3751 - 3760 of 7939 Results
Title
Year
-
RESTRICTEDTitle: Allosteric inhibition of LRRK2, where are we nowJournal Name: Biochemical Society TransactionsPublisher: Portland Press Ltd.Vol: 48Issue #: 5Start Page: 2185End Page: 2194Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1042/bst20200424Best OA location URL: https://portlandpress.com/biochemsoctrans/article-pdf/48/5/2185/896516/bst-2020-0424c.pdfCitation Count: 10
-
RESTRICTEDTitle: Apolipoprotein E ε4 genotype and risk of freezing of gait in Parkinson's diseaseJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 81Issue #:Start Page: 173End Page: 178Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2020.10.033Citation Count: 17
-
OPENTitle: Detect and correct bias in multi-site neuroimaging datasetsJournal Name: Medical Image AnalysisPublisher: Elsevier BVVol: 67Issue #:Start Page: 101879End Page: 101879Publication Date:Open Access(OA) Status: OPENLicense: publisher-specific-oaDOI - Digital Object Identifier: 10.1016/j.media.2020.101879Best OA location URL: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdfCitation Count: 85
-
OPENTitle: Microgravity: A Tool for Protein Drug DevelopmentJournal Name: International Journal of Pharmaceutical Sciences Review and ResearchPublisher: Global Research OnlineVol: 64Issue #: 2Start Page: 82End Page: 86Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.47583/ijpsrr.2020.v64i02.014Best OA location URL: https://doi.org/10.47583/ijpsrr.2020.v64i02.014Citation Count: 2
-
OPENTitle: Palliative Care for Persons Living With Parkinson DiseaseJournal Name: JAMAPublisher: American Medical Association (AMA)Vol: 324Issue #: 15Start Page: 1579End Page: 1579Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1001/jama.2020.18333Best OA location URL: https://jamanetwork.com/journals/jama/articlepdf/2771904/jama_sokol_2020_pg_200052_1602876114.33828.pdfCitation Count: 5
- Use of Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany2020OPENTitle: Use of Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in GermanyJournal Name: Journal of Alzheimer's DiseasePublisher: SAGE PublicationsVol: 78Issue #: 3Start Page: 1137End Page: 1148Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.3233/jad-200794Citation Count: 6
-
OPENTitle: What's happening in Neurology ® Clinical PracticeJournal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 95Issue #: 16Start Page: 727End Page: 727Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1212/wnl.0000000000010792Best OA location URL: https://n.neurology.org/content/neurology/95/16/727.full.pdfCitation Count: 0
- Long genes are more frequently affected by somatic mutations and show reduced expression in Alzheimer's disease: Implications for disease etiology2020OPENTitle: Long genes are more frequently affected by somatic mutations and show reduced expression in Alzheimer's disease: Implications for disease etiologyJournal Name: Alzheimer's & DementiaPublisher: WileyVol: 17Issue #: 3Start Page: 489End Page: 499Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.1002/alz.12211Best OA location URL: https://doi.org/10.1002/alz.12211Citation Count: 22
-
OPENTitle: The Human Coronavirus Receptor ANPEP (CD13) Is Overexpressed in Parkinson's DiseaseJournal Name: Movement DisordersPublisher: WileyVol: 35Issue #: 12Start Page: 2134End Page: 2136Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mds.28354Best OA location URL: https://eprints.ncl.ac.uk/file_store/production/271876/552911A9-469D-41EA-AA8A-F7B7D5C04187.pdfCitation Count: 4
- A 12-month, dose-level blinded safety and efficacy study of levodopa inhalation powder (CVT-301, Inbrija) in patients with Parkinson's disease2020OPENTitle: A 12-month, dose-level blinded safety and efficacy study of levodopa inhalation powder (CVT-301, Inbrija) in patients with Parkinson's diseaseJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 81Issue #:Start Page: 144End Page: 150Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.parkreldis.2020.10.029Best OA location URL: http://www.prd-journal.com/article/S1353802020308221/pdfCitation Count: 16